Procaps Group, S.A. ("Procaps Group") (NASDAQ: PROC) is a developer of pharmaceutical and nutraceutical solutions, medicines, and hospital supplies that reach more than 50 countries in all five continents. Procaps has a direct presence in 13 countries in the Americas and more than 5,300 collaborators working under a sustainable model. Procaps develops, manufactures, and markets over the counter (OTC) pharmaceutical products and prescription pharmaceutical drugs (Rx), nutritional supplements and high-potency clinical solutions.
Committed to Innovation for a Healthier World
Procaps Group Announces Appointment of Jose Antonio Vieira as Chief Executive Officer Starting 2024 MIAMI & BARRANQUILLA, Colombia --(BUSINESS WIRE)--Nov. 22, 2023-- Procaps Group (NASDAQ: PROC) (“Procaps”), a leading integrated LatAm healthcare and pharmaceutical conglomerate, announced today a strategic leadership transition as Ruben Minski, founder and CEO of Procaps prepares to transition November 22, 2023
Read more - ENG
Read more - ESP
Read more - PT
Copyright © 2023